Skip to main content

View full-text article in PMC

. 2017 Nov 1;8:1440. doi: 10.3389/fimmu.2017.01440

Table 1.

Clinical characteristics of the subjects.

	hCD	uGD	eGD	nGD
n (male/female)	30 (10/20)	40 (14/26)	30 (8/22)	18 (4/18)
FT3 (pmol/l)	4.35 ± 0.50	27.95 ± 13.67^a	4.45 ± 0.77^b	4.17 ± 0.42^c
FT4 (pmol/l)	13.34 ± 1.33	41.06 ± 12.83^a	11.67 ± 2.90^b	12.98 ± 2.20^c
sTSH (mIU/l)	1.93 ± 0.79	0.003 ± 0.006^a	2.10 ± 3.51^b	1.90 ± 0.83^c
TRAb (IU/l)	0.38 ± 0.25	17.33 ± 12.32^a	9.22 ± 8.30	0.72 ± 0.35^c
TPOAb (IU/ml)	0.28 ± 0.24	328.54 ± 317.2^a	358.97 ± 301.53	55.59 ± 65.66^d
TGAb (IU/ml)	1.03 ± 0.64	273.15 ± 345.57^a	139.18 ± 209.32	73.90 ± 65.66^d

^aP < 0.01, untreated GD (uGD) compared with healthy control donors (hCD).

^bP < 0.01, euthyroid GD (eGD) compared with uGD.

^cP < 0.01, TRAb negative-conversion GD (nGD) compared with uGD.

^dP < 0.05, nGD compared with uGD.